Samuel C. Wadsworth

发表

Adeno-Associated Virus Gene Therapy for Liver Disease

L. Kattenhorn, K. Clark, T. Wright, 2016, Human gene therapy.

Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence

K. Hehir, A. Smith, S. Wadsworth, 1996, Journal of virology.

Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice.

H. Romanczuk, J. Zabner, S. Wadsworth, 1999, Human gene therapy.

Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung.

P. A. Peterson, J. Kaplan, L. Gooding, 1997, Human gene therapy.

Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications.

J. S. St. George, H. Dorkin, M. Perricone, 2001, Human gene therapy.

Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis.

R. Gibson, B. Ramsey, J. Zabner, 1996, The Journal of clinical investigation.

Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.

S. Rosenberg, Y. Zhai, P. Spiess, 1996, Journal of immunology.

Adenovirus-Mediated Persistent Cystic Fibrosis Transmembrane Conductance Regulator Expression in Mouse Airway Epithelium

Canwen Jiang, J. Kaplan, J. S. St. George, 1998, Journal of Virology.

Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products

S. Wadsworth, K. Vincent, S. Piraino, 1997, Journal of virology.